Can you take Brompheniramine with Propoven?

Brompheniramine has a moderate potential interaction with Asthma.

It has been suggested that the anticholinergic effect of antihistamines may reduce the volume and cause thickening of bronchial secretions, resulting in obstruction of respiratory tract. Some manufacturers and clinicians recommend that therapy with antihistamines be administered cautiously in patients with asthma or chronic obstructive pulmonary disease.

The propofol in Propoven has a moderate potential interaction with Burns, External.

Reports of mean urinary zinc loss during propofol therapy was approximately 2.5 to 3.0 mg/day in adult patients and 1.5 to 2.0 mg/day in pediatric patients. Practitioners should consider the administration of supplemental zinc during prolonged therapy with propofol in patients who are predisposed to zinc deficiency, such as those with burns, diarrhea, and/or major sepsis. Monitoring is recommended in these patients.

Brompheniramine has a moderate potential interaction with Cardiovascular Conditions and Disorders.

Antihistamines may infrequently cause cardiovascular adverse effects related to their anticholinergic and local anesthetic (quinidine-like) activities. Tachycardia, palpitation, ECG changes, arrhythmias, hypotension, and hypertension have been reported. Although these effects are uncommon and usually limited to overdosage situations, the manufacturers and some clinicians recommend that therapy with antihistamines be administered cautiously in patients with cardiovascular disease, hypertension, and/or hyperthyroidism.

The propofol in Propoven has a major potential interaction with Cerebral Vascular Disorder.

Propofol can induce severe hypotension and/or cardiovascular depression, particularly during the induction phase of sedation or anesthesia. Use of propofol infusions for both adult and pediatric ICU sedation has been associated with a constellation of metabolic derangements and organ system failures, referred to as Propofol Infusion Syndrome, that have resulted in death. The syndrome is characterized by severe metabolic acidosis, hyperkalemia, lipemia, rhabdomyolysis,hepatomegaly, renal failure, ECG changes (ST segment elevation similar to that in Brugada syndrome) and/or cardiac failure. Therapy with propofol should be administered cautiously in patients with preexisting cardiovascular disorders, hemodynamic impairment, increased intracranial pressure, or impaired cerebral circulation.

Brompheniramine has a moderate potential interaction with COPD.

It has been suggested that the anticholinergic effect of antihistamines may reduce the volume and cause thickening of bronchial secretions, resulting in obstruction of respiratory tract. Some manufacturers and clinicians recommend that therapy with antihistamines be administered cautiously in patients with asthma or chronic obstructive pulmonary disease.

The propofol in Propoven has a moderate potential interaction with Diarrhea.

Reports of mean urinary zinc loss during propofol therapy was approximately 2.5 to 3.0 mg/day in adult patients and 1.5 to 2.0 mg/day in pediatric patients. Practitioners should consider the administration of supplemental zinc during prolonged therapy with propofol in patients who are predisposed to zinc deficiency, such as those with burns, diarrhea, and/or major sepsis. Monitoring is recommended in these patients.

Brompheniramine has a moderate potential interaction with Gastrointestinal Obstruction.

Antihistamines often have anticholinergic activity, to which elderly patients are particularly sensitive. Therapy with antihistamines should be administered cautiously, if at all, in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders. Conventional, first-generation antihistamines such as the ethanolamines (bromodiphenhydramine, carbinoxamine, clemastine, dimenhydrinate, diphenhydramine, doxylamine, phenyltoloxamine) tend to exhibit substantial anticholinergic effects. In contrast, the newer, relatively nonsedating antihistamines (e.g., cetirizine, fexofenadine, loratadine) reportedly have low to minimal anticholinergic activity at normally recommended dosages and may be appropriate alternatives.

Brompheniramine has a moderate potential interaction with Glaucoma/Intraocular Hypertension.

Antihistamines often have anticholinergic activity, to which elderly patients are particularly sensitive. Therapy with antihistamines should be administered cautiously, if at all, in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders. Conventional, first-generation antihistamines such as the ethanolamines (bromodiphenhydramine, carbinoxamine, clemastine, dimenhydrinate, diphenhydramine, doxylamine, phenyltoloxamine) tend to exhibit substantial anticholinergic effects. In contrast, the newer, relatively nonsedating antihistamines (e.g., cetirizine, fexofenadine, loratadine) reportedly have low to minimal anticholinergic activity at normally recommended dosages and may be appropriate alternatives.

The propofol in Propoven has a major potential interaction with Heart Block.

Propofol can induce severe hypotension and/or cardiovascular depression, particularly during the induction phase of sedation or anesthesia. Use of propofol infusions for both adult and pediatric ICU sedation has been associated with a constellation of metabolic derangements and organ system failures, referred to as Propofol Infusion Syndrome, that have resulted in death. The syndrome is characterized by severe metabolic acidosis, hyperkalemia, lipemia, rhabdomyolysis,hepatomegaly, renal failure, ECG changes (ST segment elevation similar to that in Brugada syndrome) and/or cardiac failure. Therapy with propofol should be administered cautiously in patients with preexisting cardiovascular disorders, hemodynamic impairment, increased intracranial pressure, or impaired cerebral circulation.

The propofol in Propoven has a moderate potential interaction with High Cholesterol.

Propofol is formulated in an oil-and-water emulsion and elevated triglycerides can occur during extended therapy. Propofol should be administered cautiously in patients with lipid disorders such as primary hyperlipoproteinemia, diabetic hyperlipemia, and pancreatitis. Each milliliter of propofol contains 0.1g of fat (1.1 kcal).

Brompheniramine has a moderate potential interaction with Hyperthyroidism.

Antihistamines may infrequently cause cardiovascular adverse effects related to their anticholinergic and local anesthetic (quinidine-like) activities. Tachycardia, palpitation, ECG changes, arrhythmias, hypotension, and hypertension have been reported. Although these effects are uncommon and usually limited to overdosage situations, the manufacturers and some clinicians recommend that therapy with antihistamines be administered cautiously in patients with cardiovascular disease, hypertension, and/or hyperthyroidism.

The propofol in Propoven has a major potential interaction with Hypotension.

Propofol can induce severe hypotension and/or cardiovascular depression, particularly during the induction phase of sedation or anesthesia. Use of propofol infusions for both adult and pediatric ICU sedation has been associated with a constellation of metabolic derangements and organ system failures, referred to as Propofol Infusion Syndrome, that have resulted in death. The syndrome is characterized by severe metabolic acidosis, hyperkalemia, lipemia, rhabdomyolysis,hepatomegaly, renal failure, ECG changes (ST segment elevation similar to that in Brugada syndrome) and/or cardiac failure. Therapy with propofol should be administered cautiously in patients with preexisting cardiovascular disorders, hemodynamic impairment, increased intracranial pressure, or impaired cerebral circulation.

Brompheniramine has a moderate potential interaction with Hypotension.

Antihistamines may infrequently cause cardiovascular adverse effects related to their anticholinergic and local anesthetic (quinidine-like) activities. Tachycardia, palpitation, ECG changes, arrhythmias, hypotension, and hypertension have been reported. Although these effects are uncommon and usually limited to overdosage situations, the manufacturers and some clinicians recommend that therapy with antihistamines be administered cautiously in patients with cardiovascular disease, hypertension, and/or hyperthyroidism.

The propofol in Propoven has a major potential interaction with Ischemic Heart Disease.

Propofol can induce severe hypotension and/or cardiovascular depression, particularly during the induction phase of sedation or anesthesia. Use of propofol infusions for both adult and pediatric ICU sedation has been associated with a constellation of metabolic derangements and organ system failures, referred to as Propofol Infusion Syndrome, that have resulted in death. The syndrome is characterized by severe metabolic acidosis, hyperkalemia, lipemia, rhabdomyolysis,hepatomegaly, renal failure, ECG changes (ST segment elevation similar to that in Brugada syndrome) and/or cardiac failure. Therapy with propofol should be administered cautiously in patients with preexisting cardiovascular disorders, hemodynamic impairment, increased intracranial pressure, or impaired cerebral circulation.

Brompheniramine has a moderate potential interaction with Liver Disease.

Limited pharmacokinetic data are available for the older, first-generation antihistamines. Many appear to be primarily metabolized by the liver, and both parent drugs and metabolites are excreted in the urine. Patients with renal and/or liver disease may be at greater risk for adverse effects from antihistamines due to drug and metabolite accumulation. Therapy with antihistamines should be administered cautiously in such patients. Lower initial dosages may be appropriate.

Brompheniramine has a moderate potential interaction with Renal Dysfunction.

Limited pharmacokinetic data are available for the older, first-generation antihistamines. Many appear to be primarily metabolized by the liver, and both parent drugs and metabolites are excreted in the urine. Patients with renal and/or liver disease may be at greater risk for adverse effects from antihistamines due to drug and metabolite accumulation. Therapy with antihistamines should be administered cautiously in such patients. Lower initial dosages may be appropriate.

The propofol in Propoven has a moderate potential interaction with Renal Dysfunction.

At high doses (2-3 grams per day), EDTA has been reported, on rare occasions, to be toxic to the renal tubules. Studies to-date, in patients with normal or impaired renal function have not shown any alteration in renal function with propofol Injectable Emulsion containing 0.005% disodium edetate. In patients at risk for renal impairment, urinalysis and urine sediment should be checked before initiation of sedation and then be monitored on alternate days during sedation.

The propofol in Propoven has a moderate potential interaction with Seizures.

Patients with seizure disorders are at increased risk of seizure activity during the recovery phase of sedation or anesthesia following administration of propofol. Clinical monitoring of seizure activity is recommended in patients with or predisposed to seizure disorders.

The propofol in Propoven has a moderate potential interaction with Sepsis.

Reports of mean urinary zinc loss during propofol therapy was approximately 2.5 to 3.0 mg/day in adult patients and 1.5 to 2.0 mg/day in pediatric patients. Practitioners should consider the administration of supplemental zinc during prolonged therapy with propofol in patients who are predisposed to zinc deficiency, such as those with burns, diarrhea, and/or major sepsis. Monitoring is recommended in these patients.

The propofol in Propoven has a major potential interaction with Tachyarrhythmia.

Propofol can induce severe hypotension and/or cardiovascular depression, particularly during the induction phase of sedation or anesthesia. Use of propofol infusions for both adult and pediatric ICU sedation has been associated with a constellation of metabolic derangements and organ system failures, referred to as Propofol Infusion Syndrome, that have resulted in death. The syndrome is characterized by severe metabolic acidosis, hyperkalemia, lipemia, rhabdomyolysis,hepatomegaly, renal failure, ECG changes (ST segment elevation similar to that in Brugada syndrome) and/or cardiac failure. Therapy with propofol should be administered cautiously in patients with preexisting cardiovascular disorders, hemodynamic impairment, increased intracranial pressure, or impaired cerebral circulation.

Brompheniramine has a moderate potential interaction with Urinary Retention.

Antihistamines often have anticholinergic activity, to which elderly patients are particularly sensitive. Therapy with antihistamines should be administered cautiously, if at all, in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders. Conventional, first-generation antihistamines such as the ethanolamines (bromodiphenhydramine, carbinoxamine, clemastine, dimenhydrinate, diphenhydramine, doxylamine, phenyltoloxamine) tend to exhibit substantial anticholinergic effects. In contrast, the newer, relatively nonsedating antihistamines (e.g., cetirizine, fexofenadine, loratadine) reportedly have low to minimal anticholinergic activity at normally recommended dosages and may be appropriate alternatives.

The propofol in Propoven has a moderate potential interaction with Zinc Deficiency.

Reports of mean urinary zinc loss during propofol therapy was approximately 2.5 to 3.0 mg/day in adult patients and 1.5 to 2.0 mg/day in pediatric patients. Practitioners should consider the administration of supplemental zinc during prolonged therapy with propofol in patients who are predisposed to zinc deficiency, such as those with burns, diarrhea, and/or major sepsis. Monitoring is recommended in these patients.